In the genesis of Alzheimer's disease (AD), converging lines of evidence suggest that amyloid- peptide (A) triggers a pathogenic cascade leading to neuronal loss. It was long assumed that A had to be assembled into extracellular amyloid fibrils or aggregates to exert its cytotoxic effects. Over the past decade, characterization of soluble oligomeric A species in the brains of AD patients and in transgenic models has raised the possibility that different conformations of A may contribute to AD pathology via different mechanisms. The receptor for advanced glycation end products (RAGE), a member of the Ig superfamily, is a cellular binding site for A. Here, we investigate the role of RAGE in apoptosis induced by distinct well characterized A conformations: A oligomers (AOs), A fibrils (AFs), and A aggregates (AAs). In our in vitro system, treatment with polyclonal anti-RAGE antibodies significantly improves SHSY-5Y cell and neuronal survival exposed to either AOs or AAs but does not affect AF toxicity. Interestingly, using site-specific antibodies, we demonstrate that targeting of the V d domain of RAGE attenuates AO-induced toxicity in both SHSY-5Y cells and rat cortical neurons, whereas inhibition of AA-induced apoptosis requires the neutralization of the C 1d domain of the receptor. Thus, our data indicate that distinct regions of RAGE are involved in A-induced cellular and neuronal toxicity with respect to the A aggregation state, and they suggest the blockage of particular sites of the receptor as a potential therapeutic strategy to attenuate neuronal death.